Before John Cullity learned how to price a medicine, finance a biotechnology company or negotiate a life-sciences transaction, he learned how to examine a patient. The sequence is the key to his career. Medicine came first, with its discipline of evidence and consequence. Economics and business arrived later, offering two more ways to ask the same stubborn question: what would it take for a promising idea to travel from a laboratory into the world?
Cullity grew up around Cottesloe Beach in Perth, on Australia's western edge, and studied medicine at the University of Western Australia. He trained further in haematology-oncology at Perth's QEII Medical Centre, then left the clinic's familiar hierarchy for a much wider syllabus. In London he completed the Royal College of Physicians examinations and studied health policy, planning and financing at the London School of Economics. At Wharton, he added an MBA. By the end of the 1990s, he could read a clinical result, a reimbursement argument and a balance sheet without needing an interpreter.
Three degrees, one problem
This was not credential collecting for its own sake. Each field supplied something the previous one could not. Clinical training makes uncertainty personal. Health economics asks who pays, how value is measured and which trade-offs a health system will tolerate. Business school adds capital, competition and organizational choice. Biotech requires all three at once, usually on a deadline and before the data feel complete.
Cullity tested that combination in unusually different institutions. His early career included work with the World Health Organization and the World Bank, plus consulting at A.T. Kearney. He moved into health economics and strategic pricing at Schering-Plough, then spent seven years at Sanofi-Aventis. There he worked first on pricing and later in business development, including buy-side transactions in oncology and diabetes. The number of licensing and merger-and-acquisition transactions across his career eventually passed 100.
What pricing teaches a physician
Pricing can sound like the least romantic corner of medicine. It is also where a therapy meets the blunt architecture of a health system. A treatment can work and still struggle to find a place if its value is hard to explain, its eligible population is unclear or its cost lands on the wrong budget. Cullity's years in health economics put him inside those arguments before he began advising young companies. That experience matters because a biotech's commercial problem rarely waits politely for the science to finish.
At Sanofi, the frame widened again. Business development meant evaluating assets that other teams had created and deciding whether evidence, strategic fit and price could be made to agree. A physician sees the proposed intervention. A buyer must also see the development burden, the competitive field, the rights being transferred and the ways a promising forecast might fail. Cullity built working relationships across venture capital and private equity while coordinating business-development activity in several therapeutic areas. The clinic had taught him to take uncertainty seriously. The transaction table taught him to give that uncertainty terms.
This helps explain his later preference for small, legible steps. He speaks less like a prophet of breakthroughs than a person arranging the next experiment. What question can the available capital answer? Which partnership removes a bottleneck? Which indication offers room to move? In biotech, patience is not the same as slowness. It is the habit of refusing to spend tomorrow's certainty today.
The move to Torreya Partners in New York in 2010 placed him squarely in the deal room. He advised life-sciences companies on mergers, acquisitions, partnering and financing, and established Torreya Insights around transaction advisory. In 2013 he created BioSynergy Partners, an independent practice connecting New York, New Jersey and Melbourne. Its geography suited Cullity: an Australian physician operating from the United States, moving between scientific teams, boards and capital markets on both sides of the Pacific.
“You want to drive around traffic, not into it.”John Cullity on choosing a development path
A molecule behind the cushion
One advisory conversation became a board career. The founders of Race Oncology, William Garner and Peter Molloy, approached Cullity for corporate advice about bisantrene, a cancer drug with a peculiar history. It had gone through years of trials and won French approval in 1990, then slipped from view during a chain of corporate takeovers. The molecule had not failed so much as lost its institutional home.
Cullity joined the Race board in April 2018 and later became chair, including a period as executive chair. The assignment demanded a certain resistance to romance. An old drug carries useful evidence, but also old assumptions, incomplete records and the temptation to treat rediscovery as destiny. Cullity's language was practical. When discussing how to find value in a busy oncology landscape, he offered the traffic rule: go around the congestion. When an early study produced a signal worth pursuing, his verdict was just as economical: “The drug is talking to us.”
Race's revival work became the most visible example of his method. Start with the evidence already earned. Decide which market and trial design make the next question answerable. Raise capital in measured stages. Avoid competing merely because everyone else has decided a field is fashionable. Cullity also put his own money into the company, participating with A$250,000 in a 2019 placement. He left the Race board in August 2023, after more than five years as a director.
Company building in two hemispheres
Cullity's work was never confined to the adviser side of the table. He had founding roles in several young biotechnology companies, including Convergent Therapeutics, NanoRetinal, Theraly and Ceramedix. Convergent brought together cancer biology, antibodies and targeted radioisotopes; Cullity served in a chief business advisory capacity during its earlier company-building period. The company has since assembled a different operating leadership team. The handover is part of the work. Biotech companies are temporary coalitions of the people needed for a particular stage.
HaemaLogiX lasted longest as a governance commitment. Cullity was a co-founder and served as an executive and director from the company's inception, helping it develop a portfolio of immunotherapy programs. In January 2024, after a decade on the board, he became chair. His appointment statement was characteristically brief: he was pleased to take the role and wanted to continue the work already underway. Alan Liddle, another co-founder, publicly described Cullity's experience and insightfulness as an asset.
Established BioSynergy Partners after his transaction-advisory work at Torreya.
Began a 12-year period as a HaemaLogiX co-founder, executive and director.
Joined Race Oncology's board, later serving as chair and executive chair.
Moved into the HaemaLogiX chair while continuing cross-border biotech work.
As NanoRetinal CEO, announced a manufacturing partnership for NAR-001.
Left the HaemaLogiX board as the company prepared for a planned Australian listing.
Leaving the chair on purpose
The end of that chairmanship says nearly as much as the appointment. In June 2026, HaemaLogiX announced that Cullity would step down after 12 years of service. The company was preparing for a planned Australian public listing. That next stage required close, consistent contact with the local investment community, he explained, and doing that from his home in the United States was difficult.
Founders do not always volunteer that the company has outgrown their seat. Cullity did. “Serving as Chair has been a privilege,” he said, while expressing confidence in the company's commercial prospects. There was pride without possession. The leadership structure had to follow the company's circumstances, not the founder's biography. Alan Liddle moved into the chair.
That decision fits the broader shape of Cullity's career. He has repeatedly entered organizations at the point where translation matters: medicine into economics, evidence into a transaction, an asset into a company, a founder-led board into public-market preparation. Translation is rarely glamorous. It is exacting and often invisible. When it works, the next group can behave as if the path was obvious all along.
The next experiment
Cullity's current operating chapter is NanoRetinal, where he is chief executive. The company is developing NAR-001, a nanoparticle-based program intended to preserve or restore vision in inherited retinal disease. In September 2025, NanoRetinal selected GBI Biomanufacturing to develop and manufacture the program. Cullity praised the partner's commitment and pointed to the regulatory standards required for manufacture. It was a CEO's statement, but also a health economist's and dealmaker's: ambition translated into capacity, process and a named next step.
A 2026 research paper listing Cullity among the NanoRetinal-affiliated authors reported preclinical findings related to delivering visual chromophore to retinal photoreceptors. It is early work, and early work deserves careful verbs. The notable point is not a promised outcome. It is that Cullity remains close to the same border he chose decades ago, where scientific possibility must acquire a development plan before it can travel.
There are louder figures in biotech, and more linear résumés. Cullity's is interesting because it keeps changing professional language without changing the underlying task. Examine the evidence. Understand the system around it. Find a route that can be financed. Put the right people around the table. Then, when the organization reaches a different road, know whether to stay in the driver's seat.